ABSTRACT
OBJECTIVE: To evaluate the efficacy and safety profile of one 30-mg nimodipine oral tablet taken three times per day (one tablet with breakfast, one with lunch, and one with dinner) or one 150-mg cinnarizine verum oral capsule taken once each day with dinner for 12 weeks. STUDY DESIGN: Comparative in a double-blind, multinational pilot study. SETTING: Tertiary referral center. PATIENTS: A total of 221 patients met the study criteria; of that total, 181 adult patients completed the study, including 135 women and 46 men whose ages ranged from 20 to 80 years. INTERVENTIONS: Two calcium antagonists were used to treat vertigo (nimodipine, 89 patients; cinnarizine, 92 patients), and all patients were maintained on the same dosage regimen until they completed 12 weeks of treatment. Patients were evaluated at 2-and 4-week intervals; an additional evaluation was made at Week 14 to determine vertigo recurrence in the posttreatment period. MAIN OUTCOME MEASURES: The response was evaluated by using the vertigo severity index, a count of vertigo episodes in a given time period. Each episode is weighted according to its intensity. RESULTS: Nimodipine treatment decreased the incidence of moderate vertigo episodes by 78.8% and decreased severe vertigo episodes by 85.0%. Cinnarizine treatment decreased the incidence of moderate vertigo episodes by 65.8% and decreased severe vertigo episodes by 89.8%. Nimodipine and cinnarizine exhibited similar safety profiles. Only two patients withdrew from the study because of adverse events possibly related to the study drug. One patient withdrew from the cinnarizine group because of headache, and one patient withdrew from the nimodipine group because of lipothymia. CONCLUSION: These data confirm the marked efficacy of both nimodipine and cinnarizine in the treatment of vestibular vertigo.
Subject(s)
Calcium Channel Blockers/administration & dosage , Cinnarizine/therapeutic use , Nimodipine/therapeutic use , Vertigo/drug therapy , Adult , Aged , Aged, 80 and over , Calcium Channel Blockers/adverse effects , Calcium Channel Blockers/therapeutic use , Cinnarizine/administration & dosage , Cinnarizine/adverse effects , Drug Administration Schedule , Electronystagmography , Female , Humans , International Cooperation , Male , Middle Aged , Nimodipine/administration & dosage , Nimodipine/adverse effects , Pilot Projects , Recurrence , Severity of Illness Index , Vertigo/physiopathologyABSTRACT
Se realizó un estudio clínico serológico prospectivo en 200 niños con patología oncológica para determinar la frecuencia y riesgo de toxoplasmosis en esta población. El estudio se efectuó por reacción de inmunofluorescencia indirecta para T. gondii, considerándose títulos positivos aquellos * 1:16. De ellos, 75 (37,5%) presentaron serología positiva, 53 (26,5%) títulos bajos, 15 (7,5%) títulos medianos y 7 (3,5%) títulos altos. De acuerdo a la patología de base 41,6% de los tumores óseos presentó toxoplasmosis, el 35,2% de las leucemias y el 30% de los linfomas. Todos los niños seropositivos fueron controlados periódicamente mediante examen clínico y relación de inmunofluorescencia indirecta en suero. Se demuestra que los niños oncológicos tienen un riesgo 2,86 veces mayor de presentar toxoplasmosis (p < 0,05) con un intervalo de confianza de 1,884,32; aquéllos con tumores óseos presentan un riesgo 4,4 veces mayor. En relación a lo descrito para población normal, en cambio, los pacientes portadores de linfoma no presentaron mayor riesgo de toxoplasmosis que la población pediátrica sin esta patología
